Scinovex
article Open AccessTop 1% cited

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Neurology · 2015 · Vol. 85(2) · pp. 177–189

Abstract

Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.

Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSystemic Lupus Erythematosus ResearchNeuromyelitis opticaMedicineMultiple sclerosisNeuroimagingConsensus conferenceSpinal cordSerologyPathologyOptic neuritisSpectrum disorder

MeSH terms

HumansNeuromyelitis Optica

Funding

  • GlaxoSmithKline
  • Sanofi
  • Biogen
  • Viropharma
  • Teva Pharmaceutical Industries
  • Alexion Pharmaceuticals
  • Guthy-Jackson Charitable Foundation
  • European Committee for Treatment and Research in Multiple Sclerosis
  • Acorda Therapeutics
  • Multiple Sclerosis Society of Canada
  • Eisai
  • Ministry of Education, Science and Technology
  • Astellas Pharma
  • Teijin Pharma
  • Mitsubishi Tanabe Pharma Corporation
  • Ono Pharmaceutical
  • National Institutes of Health
  • Novartis Pharma
  • Chugai Pharmaceutical
  • Daiichi Sankyo Europe
Citations
4,407
FWCI
212.28
field-weighted impact
References
61
Percentile
100%
vs. same field & year
Citations per year
Cited by
References
The spectrum of neuromyelitis optica
The Lancet Neurology · 2007 · 2,163 citations
Brain Abnormalities in Neuromyelitis Optica
Archives of Neurology · 2006 · 680 citations
Revised diagnostic criteria for neuromyelitis optica
Neurology · 2006 · 2,570 citations
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
The Journal of Experimental Medicine · 2005 · 2,250 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders · Scinovex